Loading publications…
The last 5 uploaded publications
Phase 1b study of immunocytokine simlukafusp alfa (FAP-IL2v) combined with pembrolizumab for treatment of advanced and/or metastatic melanoma
Eva Muñoz‐Couselo, Ainara Soria Rivas, Shahneen Sandhu, Georgina V. Long, Miguel F. Sanmamed, Anna Spreafico, Elizabeth I. Buchbinder, Mario Sznol, Hans Prenen, А. А. Феденко, Mohammed Milhem, Ana Arance, Jean‐Jacques Grob, Lev Demidov, Caroline Robert, Christin Habigt, Stefan Evers, Nassim Sleiman, David Dejardin, Caroline Ardeshir, Nicole Alice Martin, Christophe Boetsch, Jehad Charo, Volker Teichgräber, Anton Kraxner, Nino Keshelava, Oliver Bechter (2025). Phase 1b study of immunocytokine simlukafusp alfa (FAP-IL2v) combined with pembrolizumab for treatment of advanced and/or metastatic melanoma. , DOI: https://doi.org/10.1158/2767-9764.crc-24-0601.
Article61 days agoFigure 2 from Phase Ib Study of Immunocytokine Simlukafusp Alfa (FAP-IL2v) Combined with Pembrolizumab for Treatment of Advanced and/or Metastatic Melanoma
Eva Muñoz‐Couselo, Ainara Soria Rivas, Shahneen Sandhu, Georgina V. Long, Miguel F. Sanmamed, Anna Spreafico, Elizabeth I. Buchbinder, Mario Sznol, Hans Prenen, А. А. Феденко, Mohammed Milhem, Ana Arance, Jean‐Jacques Grob, Lev Demidov, Caroline Robert, Christin Habigt, Stefan Evers, Nassim Sleiman, David Dejardin, Caroline Ardeshir, Nicole Alice Martin, Christophe Boetsch, Jehad Charo, Volker Teichgräber, Anton Kraxner, Nino Keshelava, Oliver Bechter (2025). Figure 2 from Phase Ib Study of Immunocytokine Simlukafusp Alfa (FAP-IL2v) Combined with Pembrolizumab for Treatment of Advanced and/or Metastatic Melanoma. , DOI: https://doi.org/10.1158/2767-9764.28471007.
Preprint61 days agoTable S4 from Phase Ib Study of Immunocytokine Simlukafusp Alfa (FAP-IL2v) Combined with Pembrolizumab for Treatment of Advanced and/or Metastatic Melanoma
Eva Muñoz‐Couselo, Ainara Soria Rivas, Shahneen Sandhu, Georgina V. Long, Miguel F. Sanmamed, Anna Spreafico, Elizabeth I. Buchbinder, Mario Sznol, Hans Prenen, А. А. Феденко, Mohammed Milhem, Ana Arance, Jean‐Jacques Grob, Lev Demidov, Caroline Robert, Christin Habigt, Stefan Evers, Nassim Sleiman, David Dejardin, Caroline Ardeshir, Nicole Alice Martin, Christophe Boetsch, Jehad Charo, Volker Teichgräber, Anton Kraxner, Nino Keshelava, Oliver Bechter (2025). Table S4 from Phase Ib Study of Immunocytokine Simlukafusp Alfa (FAP-IL2v) Combined with Pembrolizumab for Treatment of Advanced and/or Metastatic Melanoma. , DOI: https://doi.org/10.1158/2767-9764.28470971.
Preprint61 days agoTable 2 from Phase Ib Study of Immunocytokine Simlukafusp Alfa (FAP-IL2v) Combined with Pembrolizumab for Treatment of Advanced and/or Metastatic Melanoma
Eva Muñoz‐Couselo, Ainara Soria Rivas, Shahneen Sandhu, Georgina V. Long, Miguel F. Sanmamed, Anna Spreafico, Elizabeth I. Buchbinder, Mario Sznol, Hans Prenen, А. А. Феденко, Mohammed Milhem, Ana Arance, Jean‐Jacques Grob, Lev Demidov, Caroline Robert, Christin Habigt, Stefan Evers, Nassim Sleiman, David Dejardin, Caroline Ardeshir, Nicole Alice Martin, Christophe Boetsch, Jehad Charo, Volker Teichgräber, Anton Kraxner, Nino Keshelava, Oliver Bechter (2025). Table 2 from Phase Ib Study of Immunocytokine Simlukafusp Alfa (FAP-IL2v) Combined with Pembrolizumab for Treatment of Advanced and/or Metastatic Melanoma. , DOI: https://doi.org/10.1158/2767-9764.28470986.
Preprint61 days agoFigure S1 from Phase Ib Study of Immunocytokine Simlukafusp Alfa (FAP-IL2v) Combined with Pembrolizumab for Treatment of Advanced and/or Metastatic Melanoma
Eva Muñoz‐Couselo, Ainara Soria Rivas, Shahneen Sandhu, Georgina V. Long, Miguel F. Sanmamed, Anna Spreafico, Elizabeth I. Buchbinder, Mario Sznol, Hans Prenen, А. А. Феденко, Mohammed Milhem, Ana Arance, Jean‐Jacques Grob, Lev Demidov, Caroline Robert, Christin Habigt, Stefan Evers, Nassim Sleiman, David Dejardin, Caroline Ardeshir, Nicole Alice Martin, Christophe Boetsch, Jehad Charo, Volker Teichgräber, Anton Kraxner, Nino Keshelava, Oliver Bechter (2025). Figure S1 from Phase Ib Study of Immunocytokine Simlukafusp Alfa (FAP-IL2v) Combined with Pembrolizumab for Treatment of Advanced and/or Metastatic Melanoma. , DOI: https://doi.org/10.1158/2767-9764.28470998.
Preprint61 days ago